UroGen Pharma (URGN) has come into focus after announcing a settlement and license agreement with Teva Pharmaceuticals covering Jelmyto. The deal clarifies future generic entry timing and removes ongoing patent litigation risk around this cancer treatment.

Recent news around Jelmyto has come as the stock cools slightly in the very short term, with the 30 day share price return down 8.67% and the 7 day share price return down 4.55%. This has occurred even though momentum over the past quarter and year has been strong, including a 90 day share price return of 34.86% and a one year total shareholder return of 264.31%.

If you are looking beyond a single biotech story, this could be a useful moment to compare UroGen with other healthcare focused opportunities using our screener for 39 healthcare AI stocks

With the Jelmyto patent overhang now clearer, UroGen is trading around $26.85, with a value score of 4 and an intrinsic value estimate that is lower than today’s price. Is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 25.6% Undervalued

Compared with the narrative fair value of $36.11, UroGen Pharma’s last close at $26.85 leaves a sizable valuation gap that hinges on future execution and profitability.

The shift toward minimally invasive, office-based therapies (away from repeated surgeries) and demonstrated long-term durability data for ZUSDURI directly align with industry-wide transitions in care standards, supporting broader market penetration and the company's ability to command premium pricing, thus improving future net margins and profitability. Strong early feedback from physicians and payers, paired with investment in commercial infrastructure and robust cash reserves, positions UroGen to effectively leverage growing healthcare spending and greater access to therapies, supporting both revenue growth and margin expansion as scale is achieved.

Want to see what kind of revenue surge and margin flip this narrative is built on? The story blends rapid top line expansion with a profit profile usually reserved for mature franchises. Curious how those projections line up against the discount rate and future earnings multiple that underpin the $36.11 figure? The full narrative lays out the numbers behind that call.

Result: Fair Value of $36.11 (UNDERVALUED)

However, the story still hinges on UroGen narrowing heavy losses and managing high 2025 operating expenses of US$215 to US$225 million, while reimbursement or trial setbacks could quickly pressure the bullish case.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: What The Sales Multiple Is Telling You

That narrative fair value of $36.11, implying UroGen is 25.6% undervalued, sits alongside a different message from the current sales multiple. The stock trades on a P/S of 9.3x, slightly cheaper than the US Biotechs average at 10.1x, but above its own fair ratio of 12x. It may be considered good value yet not obviously a bargain, so which signal matters more for you?

Next Steps

Sentiment around UroGen is clearly mixed, with clear risks on one side and real upside potential on the other. Move quickly to review the full picture for yourself and then weigh the company’s 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop at just one stock, you miss the bigger picture. Broaden your watchlist now with a few focused idea lists built from clear, transparent data.

• Target potential mispricing by scanning companies that look cheap on quality and fundamentals using our 49 high quality undervalued stocks.
• Strengthen your downside protection by highlighting businesses with sturdy finances and resilient balance sheets through the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by spotting underfollowed opportunities with solid metrics via the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.